- $390.46m
- $258.57m
- $0.02m
Annual income statement for Altimmune, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 8.19 | 4.41 | -0.068 | 0.426 | 0.02 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 63 | 101 | 87.7 | 96.4 | 103 |
| Operating Profit | -54.8 | -96.9 | -87.7 | -95.9 | -103 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -54.5 | -97.1 | -84.9 | -88.4 | -95.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -49 | -97.1 | -84.7 | -88.4 | -95.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -49 | -97.1 | -84.7 | -88.4 | -95.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -49 | -97.1 | -84.7 | -88.4 | -95.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.91 | -2.08 | -1.81 | -1.43 | -1.34 |